Trafalgar 10-Q: Going Concern Reaffirmed, $111 Cash, Material Weakness Disclosed
TRFA sits 32% above its 52-week low of $0.75 on elevated volume (2.2× avg).
Summary
Trafalgar reported $111 of cash, zero revenue and a reaffirmed going-concern warning, with nine-month net income of $487,667 coming entirely from non-cash debt-cancellation gains. The company is being funded by Chairman loans and needs new capital to survive.
Key Events · Earnings and Guidance · TRFA
-
Going Concern Doubt Reaffirmed
Management concluded that substantial doubt about the ability to continue as a going concern has not been alleviated for the one-year period following issuance of the financial statements.
-
Cash Down to $111
Cash fell from $815 at December 31, 2025 to $111 at September 30, 2026; the only financing inflow was $96,124 of related-party loans from Chairman Porfirio Sanchez Talavera.
-
Profit Is Non-Cash Accounting
Nine-month net income of $487,667 came from a $621,450 gain on cancellation of debt and a $1,483 preferred-stock gain; the third quarter alone was a $90,335 net loss on zero revenue.
-
Material Weakness in Controls
Management concluded disclosure controls and procedures were not effective as of September 30, 2026 due to material weaknesses, including limited accounting resources and insufficient segregation of duties.
Analysis · TRFA · Life Sciences
Trafalgar has essentially no money left. Cash stood at $111 on September 30, 2026, down from $815 at year-end, and management explicitly says substantial doubt about continuing as a going concern has not been alleviated for the year after issuance. The $487,667 of nine-month net income is an accounting artifact, not operations: it comes from a $621,450 non-cash gain on cancelling related-party debt and accrued officer pay, while the quarter itself lost $90,335 and the company booked zero revenue. The only cash coming in is $96,124 of advances from Chairman Porfirio Sanchez Talavera, who now holds all the preferred stock and controls the company. Management also concluded disclosure controls were not effective because of material weaknesses, and the post-quarter charter restatement leaves Series B preferred with at least 51% of voting power. Any path forward requires new financing, which would be heavily dilutive to the roughly 199,153 common shares outstanding.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TRFA was trading at $0.99 on OTC in the Life Sciences sector, with a market capitalization of approximately $196.8K. The 52-week trading range was $0.75 to $44,995.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.